Loading...
NPI 1407113020 · Tampa, FL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Laboratory Of Florida LLC is a clinical medical laboratory provider located in Tampa, Florida. This profile covers 148 Medicare and 101 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Laboratory Of Florida LLC |
| Address | 8412 Wilsky Blvd |
| City | Tampa |
| State | FL |
| ZIP | 33615 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | April 19, 2012 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $12.2M |
| Medicaid | $664.4K |
LABORATORY OF FLORIDA LLC is a clinical diagnostic laboratory with concentrated molecular infectious-disease testing in its Medicare portfolio; three Medicare codes account for 60.5% of Medicare revenue, driven by high-volume nucleic acid amplification tests such as 87150 and 87801 and a large volume of specimen-travel allowance claims under P9603. The code mix (many amplified probe techniques and multiplex pathogen panels) indicates the operation focuses on high-throughput molecular diagnostics and specimen collection logistics rather than only routine chemistry panels.
Revenue concentration on Medicare is pronounced: the precomputed top-3 share of 60.5% indicates the lab’s Medicare revenue is heavily dependent on a small set of molecular/infectious-disease and specimen-collection codes. Notably, 87150 alone contributes $3.5M (30.5% of Medicare revenue) and 87801 contributes $2.1M (18.4%), so shifts in utilization or reimbursement for these codes would materially affect overall Medicare income.
On Medicaid the lab also shows concentration in a few codes: the top 3 Medicaid codes account for 58.8% of total Medicaid revenue, with 87801 representing $154K (25.6%) and U0003 contributing $131.8K (21.9%). This pattern suggests the lab’s Medicaid business similarly centers on infectious-disease molecular testing and COVID-related high-throughput testing.
Payer mix is imbalanced in scale: the provider reported Total Medicare revenue of $12.2M versus Total Medicaid revenue of $664.4K, indicating Medicare dominates the revenue base by a wide margin. While both payers show similar service-line focus (molecular infectious testing), Medicaid constitutes a relatively small portion of the lab’s lifetime public-payer receipts.
Competitive standing on Medicare is exceptionally strong for multiple molecular codes: 87150 ranks #4 of 190 providers nationally (98th percentile; labeled an extreme outlier) and 87801 ranks #3 of 561 providers nationally (100th percentile; extreme outlier). Several additional nucleic-acid codes (for MRSA, group B Strep, Strep A, Candida, etc.) are also at or above the 97–100th percentiles, signaling this lab is a major national volume player for many targeted molecular assays.
By contrast, in-state Medicaid positions are mixed but include leadership in specific tests: 87801 ranks #3 of 89 providers in-state (98th percentile) and 87471 ranks #1 of 4 providers in-state (100th percentile). Other Medicaid codes such as U0003 and 80053 are high-volume but sit lower in statewide rank (U0003 at #36 of 320, 89th percentile; 80053 at #35 of 642, 95th percentile), indicating strong but not uniformly dominant market share across all Medicaid services.
Operational detail: P9603 shows extremely large claim volume on Medicare (1.3M claims, $1 avg, $1.3M revenue) and ranks #9 of 267 providers nationally (97th percentile; notably above typical national volume), which reflects substantial specimen pickup/travel activity and suggests logistics and collection services are an important revenue and operational component of the business. This heavy use of specimen-collection/travel allowances differentiates the lab from peers that primarily bill on-site testing only.
Tenure: the provider NPI was enumerated on 2012-04-19 (~14 years ago), indicating an established presence in the market; the longevity combined with concentrated high-volume molecular testing suggests the lab has built sustained capacity and workflows for these assays over time.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
148 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 102,720 | $30 | $3.5M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 30,570 | $70 | $2.1M |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 1,339,420 | $1 | $1.3M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 21,190 | $30 | $720.5K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 10,170 | $30 | $345.8K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 10,130 | $30 | $344.4K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 9,040 | $30 | $307.3K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 9,030 | $30 | $307.1K |
| 87563 | he lab analyst performs a test on a patient specimen such as blood, for Mycoplasma genitalium antigen detection using amplified nucleic acid probe technique. | 9,020 | $30 | $306.6K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 8,560 | $30 | $291.1K |
Showing 1–10 of 148
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 148 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
148 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| P9603 | 3 | 40 | 43,600 | $1 | $290.1K |
| 87798 | 43 | 110 | 590 | $30 | $218.6K |
| 87150 | 1 | 40 | 1,660 | $30 | $173.2K |
| 87801 | 2 | 60 | 450 | $70 | $166.5K |
| 87536 | 8 | 10 | 90 | $80 | $100.3K |
| 82652 | 7 | 10 | 470 | $40 | $93.8K |
| 87481 | 2 | 80 | 340 | $30 | $72.8K |
| 87511 | 12 | 10 | 220 | $30 | $60.4K |
| 86235 | 38 | 40 | 220 | $20 | $57.9K |
| U0003 | 20 | 50 | 190 | $70 | $47.1K |
Showing 1–10 of 148
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
101 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 38,510 | $1 | $154K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 10,140 | $10 | $131.8K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 67,700 | $1 | $67.7K |
| 87471 | The lab analyst performs a test for Bartonella henselae and Bartonella quintana using amplified nucleic acid probe technique. | 5,680 | $10 | $51.1K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 46,450 | $1 | $46.5K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 23,020 | $1 | $46K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 7,450 | $1 | $29.8K |
| 80048 | The lab analyst performs a basic metabolic pane (BMP) test in which he measures the blood level of eight chemicals including total calcium, sodium, potassium, chloride, carbon dioxide, glucose, blood… | 14,380 | $1 | $14.4K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 9,620 | $1 | $9.6K |
| 83880 | The lab analyst measures the amount of natriuretic peptide, a hormone made by heart muscle cells, in the patient specimen. Blood levels of the hormone increase in patients with congestive heart… | 4,130 | $1 | $8.3K |
Showing 1–10 of 101
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
101 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 36 | 320 | 750 | $40 | $232.7K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 35 | 640 | 4,400 | $10 | $193.4K |
| 84520 | The lab analyst performs a test to measure the amount of urea nitrogen in patient blood. | 295 | 300 | 1,170 | $60 | $186K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 37 | 70 | 180 | $20 | $178K |
| 82310 | The lab analyst measures the calcium level, primarily on a serum sample. | 203 | 220 | 880 | $50 | $151.3K |
| 83970 | Parathyroid hormone test measures the level of PTH in the blood. This test is done to ascertain the level of calcium and evaluate the parathyroid function. | 95 | 460 | 510 | $50 | $110.2K |
| 87389 | The lab analyst performs a test to screen for human immunodeficiency virus, called HIV. The test screens for antigens of the HIV 1 virus and antibodies to the HIV 1 and HIV 2 viruses using an… | 54 | 100 | 370 | $10 | $106K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 275 | 340 | 720 | $10 | $100.6K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 3 | 90 | 320 | $20 | $100.3K |
| 84155 | The lab analyst performs the technical lab test to quantitate total protein in a serum, plasma, or whole blood specimen using one of several assay methods, excluding refractometry. Total protein is a… | 202 | 250 | 680 | $60 | $94.3K |
Showing 1–10 of 101
Other providers in the same ZIP code as Laboratory Of Florida LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Renato J. Aves, LLC | FL | Oral and Maxillofacial Surgery (Dentist) | $0 | $30.1M |
| Accurate Health Services Corp | FL | Home Health Agency | $0 | $17.3M |
| Bayside Pediatrics, Inc | FL | Pediatrics Physician | $0 | $7.5M |
| Mayelin Matos | FL | Nurse Practitioner | $3.4M | $0 |
| Gulf Coast Dermatopathology Laboratory, Inc. | FL | Clinical Medical Laboratory | $2.3M | $4.6K |
| David Sable | FL | Dermatology Physician | $557.3K | $90 |
| Skip Alderson | FL | Diagnostic Radiology Physician | $400.6K | $500 |
| Robert Novaco | FL | Diagnostic Radiology Physician | $253.2K | $0 |
| Daniel Ruan | FL | Surgery Physician | $228.2K | $0 |
| Kevin Parrack | FL | Surgery Physician | $221.7K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.